Immunocore Holdings plc (IMCR) 株式分析

企業概要

Immunocore Holdings plc is a biotechnology enterprise focused on the development and commercialization of immunomodulating medicines designed to treat patients suffering from cancer, infectious diseases, and autoimmune conditions across the United States, Europe, and international markets. The company operates within the healthcare sector, specifically in the biotechnology industry, where its primary value proposition lies in advancing novel therapeutic modalities that modulate the immune system to target specific pathological conditions. With a market capitalization of $1.61B and an annual revenue of $400.02M, the firm represents a significant entity in the specialized pharmaceutical landscape, supported by a workforce of 524 employees. These valuation and revenue figures indicate that the company holds a substantial market presence relative to peers in the early-to-mid stage of commercialization, suggesting a robust operational scale for a biotechnology firm that is still refining its profitability profile while expanding its product portfolio.

財務健全性

The company reported a revenue of $400.02M for the trailing twelve months, accompanied by a net income of $-35,514,000 and an EBITDA of $-22,359,000, revealing a cost structure where significant operating expenses, likely driven by research and development and commercialization costs, exceed current revenue generation. Despite the net loss, the firm generated a positive free cash flow of $23.96M, which provides essential financial flexibility to fund ongoing clinical trials, operational expansion, and strategic initiatives without immediate reliance on external equity financing. The margin analysis shows a gross margin of 96.5%, indicating highly efficient production and pricing of core products, while the operating margin stands at 0.0% and the profit margin is negative at -8.9%, highlighting the intense investment phase typical of biotechnology companies where operating costs are substantial relative to revenue. On the balance sheet, the company holds $864.15M in cash against $436.69M in debt, resulting in a debt-to-equity ratio of 114.61, which characterizes a leveraged position given the high equity denominator in the ratio calculation despite the absolute cash surplus. The current ratio is a robust 4.04, indicating that the company possesses more than four times the liquid assets required to cover its short-term liabilities, thereby ensuring strong short-term liquidity. Return on Equity is negative at -9.6% and return on assets is -1.5%, metrics that reveal that management has yet to generate positive returns on the capital deployed, a common characteristic for biotechnology firms still developing their primary revenue streams.

バリュエーション評価

Valuation metrics for Immunocore Holdings plc include a trailing P/E ratio that is not available (N/A) and a forward P/E of -22.56, implying that the market is pricing in future earnings growth that is currently masked by the company's present net losses. The price-to-book ratio is 4.23, suggesting that the market values the company at a significant premium over its tangible book value, reflecting investor confidence in the potential value of its intangible assets and pipeline. The price-to-sales ratio is 4.03, and the EV/EBITDA is -53.01, indicating that traditional valuation multiples are skewed by negative earnings and that investors are relying on revenue-based metrics to assess the firm's worth. Regarding trading range, the 52-week high is $40.72 and the 52-week low is $23.15; without the specific current share price provided in the source text, the precise percentage deviation from these levels cannot be calculated, but the spread suggests a trading range of approximately 43% between the highest and lowest points of the past year. The beta is 0.83, which indicates that the stock's price volatility is lower than that of the broader market, suggesting that the company's share price tends to move with less intensity than the overall market index during periods of fluctuation.

Growth & Income

Revenue growth year-over-year is 24.3%, demonstrating a strong expansion in top-line sales, whereas earnings growth is not available (N/A) due to the company's current unprofitable status, implying that revenue expansion is currently outpacing any potential earnings generation as the firm reinvests heavily in growth. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm retains all of its earnings to fund operations and development rather than distributing income to shareholders. Since the company is not a dividend payer, the strategy clearly prioritizes capital allocation toward research and development and commercial expansion to build long-term value rather than providing immediate income returns. In summary, Immunocore Holdings plc presents a growth-oriented profile characterized by rapid revenue expansion and a zero-dividend policy that aligns with the typical lifecycle of a biotechnology company focused on product pipeline development.